Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylcarbate SCHEMBL6824434 | 0.83 | SLC1A3 (0.32) | TSHRALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL5589932 | 0.83 | ALDH1A1 (0.34) | TSHRALDH1A1CHRNB2CHRNA4CHRM2 | |
| Acetone SCHEMBL593191 | 0.82 | LMNA (0.43) | TSHRALDH1A1 | |
| SCHEMBL28324219 | 0.80 | ALDH1A1 (0.35) | TSHRALDH1A1 | |
| Acetic Acid SCHEMBL10711426 | 0.79 | FFAR3 (0.47) | TSHRALDH1A1 | |
| SCHEMBL10829544 | 0.79 | CHRM1 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Acetamide SCHEMBL11118916 | 0.77 | LMNA (0.50) | TSHRALDH1A1CHRM2CHRM4CHRM5 | |
| Isopropyl Alcohol SCHEMBL22551253 | 0.76 | ALDH1A1 (0.43) | TSHRALDH1A1CHRNB2CHRNA4CHRM2 | |
| Bicarbonate SCHEMBL6258274 | 0.76 | TP53 (0.39) | TSHRALDH1A1 | |
| SCHEMBL7993349 | 0.75 | HTR1A (0.36) | ALDH1A1CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 531 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105418635-A | Synthesis method of thienopyridine medical intermediate | SHANGHAI INST TECHNOLOGY | 2016-03-23 | — | — | CN | claimed |
| CN-103935987-B | A kind of CO 2the preparation method of responsiveness functional graphene oxide | TONGJI UNIVERSITY (CN) | 2015-10-21 | — | — | CN | claimed |
| CN-103935987-A | CO2-responsive functionalized graphene oxide preparation method | UNIV TONGJI | 2014-07-23 | — | — | CN | claimed |
| CN-101891758-A | Method for synthesizing 7-imethylamino-2, 2-dimethyl-6-ene-3, 5-suberaldehyde-O, O-boron difluoride | BEIJING AGLAIA TECHNOLOGY & DEV CO LTD | 2010-11-24 | — | — | CN | claimed |
| CN-101891725-A | 2-methyl-6-tert-butyl-4-dicyanmethylene-4H-pyran synthesis method | BEIJING AGLAIA TECHNOLOGY & DEV CO LTD | 2010-11-24 | — | — | CN | claimed |
| CN-100420697-C | Method of preparing trichloro sucrose-6-organic acid ester | HEBEI SUKERUI SCI & TECH CO LT (CN) | 2008-09-24 | — | — | CN | claimed |
| CN-1948326-A | Method of preparing trichloro sucrose-6-organic acid ester | HEBEI SUKERUI SCI & TECH CO LT (CN) | 2007-04-18 | — | — | CN | claimed |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260060900-A1 | DENTAL COMPOSITE RESIN KIT | SHOFU INC. (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20250064686-A1 | DENTAL CURABLE COMPOSITION CONTAINING ULTRAVIOLET ABSORBER | SHOFU INC (JP) | 2025-02-27 | — | — | US | disclosed |
| EP-4473954-A1 | DENTAL CURABLE COMPOSITION CONTAINING ULTRAVIOLET ABSORBER | Shofu Inc. (JP) | 2024-12-11 | — | — | EP | disclosed |
| US-20240360084-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS INC (US) | 2024-10-31 | — | — | US | disclosed |
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-4246409-A | ANTIDIARRHEAL AGENTS | WILLIAM H. RORER, INC. (US) | 1981-01-20 | — | — | US | disclosed |
| EP-0016277-A1 | 2-Carbonyl-3-hydroxy-alkenonitriles, their use as anti-arthritic agents and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-10-01 | — | — | EP | disclosed |
| US-4225315-A | Triazinones from amidinoureas | WILLIAM H. RORER, INC. (US) | 1980-09-30 | — | — | US | disclosed |
| WO-1980000964-A1 | ANTI-INFLAMMATORY AGENTS INCLUDING 2-CARBONYL-3-HYDROXY-2-ALKENONITRILES | AMERICAN CYANAMID CO (US) | 1980-05-15 | — | — | WO | disclosed |
| US-4197310-A | ANTIARTHRITIC, ANTIINFLAMMATORY, PREVENT JOINT DETERIORATION | AMERICAN CYANAMID COMPANY (US) | 1980-04-08 | — | — | US | disclosed |
| US-4181677-A | ANTIINFLAMMATORY AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-01-01 | — | — | US | disclosed |
| US-4173650-A | ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060900-A1 | DENTAL COMPOSITE RESIN KIT | BOLA2; BOLA2B, LBR, COL2A1 | TSHR 3276/4885ALDH1A1 314/4885CHRNB2 2014/4885 |
| US-20250064686-A1 | DENTAL CURABLE COMPOSITION CONTAINING ULTRAVIOLET ABSORBER | ERCC1, DSC1, CRYAA | TSHR 4039/4885ALDH1A1 479/4885CHRNB2 3355/4885 |
| US-20240360084-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | TSHR 1233/4885ALDH1A1 672/4885CHRNB2 3230/4885 |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | TSHR 120/4885ALDH1A1 1029/4885CHRNB2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.